GHK-Cu Peptide Study: Route May Shape Brain Aging

A growing body of researchers is turning to endogenous peptides — molecules the body already produces — in search of therapies that target the biological roots of cognitive aging. A June 2026 preprint study published in Research Square by Mazzola, Rosenfeld, Tucker, and colleagues adds an important and nuanced chapter to that conversation, suggesting that how a peptide is delivered may matter just as much as what is delivered. The study examined GHK-Cu, a naturally occurring copper-binding tripeptide that declines with age, and found that different administration routes produced distinct molecular fingerprints in the aging brain — even when both routes improved certain measures of cognitive function.

What This Study Found

Researchers administered GHK-Cu (at a dose of 15 mg/kg) to aged C57BL/6J mice — approximately 20 to 21 months old, an age that roughly corresponds to late middle age or early senescence in mouse biology — via two different routes: short-term intraperitoneal (IP) injection over five days, or longer-term intranasal (IN) delivery over eight weeks. The primary outcome was hippocampal-dependent spatial learning, assessed through an escape latency task, with molecular effects evaluated through immunohistochemistry and bulk RNA sequencing of hippocampal tissue.

The behavioral findings were striking in their divergence. Intranasal GHK-Cu improved escape latency across multiple trials (Trials 2–4) in both male and female mice (P < 0.05), suggesting a more consistent and sustained cognitive benefit. Intraperitoneal administration, by contrast, produced a transient improvement in males during Trial 2 only (P < 0.05) and did not produce meaningful improvement in females.

The molecular data revealed equally distinct patterns. Intranasal delivery was associated with suppression of oxidative phosphorylation — a key metabolic pathway implicated in aging biology — in both sexes (male normalized enrichment score [NES] –5.44, female NES –4.20; FDR < 0.0001), along with downregulation of MYC target pathways and, in females, attenuation of PI3K-AKT-mTOR signaling. These are pathways frequently associated with cellular aging and longevity biology. The researchers interpret this pattern as consistent with a sustained, aging-targeted biological program.

Intraperitoneal treatment told a different molecular story. Rather than suppressing metabolic activity, IP dosing activated oxidative phosphorylation in females (NES 4.97; FDR < 0.001) and upregulated DNA repair pathways (NES 5.58; FDR < 0.001) and MYC targets, suggesting engagement of acute stress-response and cellular repair mechanisms rather than a longevity-associated program.

On the protein level, intranasal treatment increased synaptophysin — a marker of synaptic integrity — in females (P < 0.001) and reduced GFAP, a marker of neuroinflammatory astrocyte activation, in both sexes (P < 0.01). Intraperitoneal treatment reduced TGF-β, GFAP, and MCP-1 in males, and decreased p21 — a senescence-associated cell cycle inhibitor — in females (P < 0.0001).

The study suggests that cognitive improvement in aged animals can arise from meaningfully different underlying biological states, and that administration route and duration of exposure are key variables in determining which biological program is engaged.

Clinical Significance

The clinical implications of these findings, while preliminary and requiring validation in human trials, are conceptually important for the field of geroscience and peptide therapeutics.

First, the study raises the possibility that GHK-Cu may engage distinct mechanisms depending on how it reaches the brain. Intranasal delivery offers a relatively direct route to the central nervous system, potentially bypassing metabolic processing that occurs with systemic injection. The longer exposure duration associated with the intranasal protocol in this study may also contribute to the more sustained transcriptomic changes observed. The researchers note that their findings cannot yet disentangle the independent contributions of route versus duration.

Second, the sex-specific differences documented throughout the study are scientifically significant. Female mice responded differently from males across nearly every outcome measure, reinforcing the importance of including sex as a biological variable in aging research. These differences may have downstream relevance for how clinical protocols are eventually designed and individualized.

Third, the suppression of the mTOR and MYC pathways observed with intranasal treatment aligns with well-established longevity biology. Both pathways are implicated in cellular senescence, metabolic dysfunction, and age-related disease. The observation that GHK-Cu may modulate these pathways in hippocampal tissue — even transiently and in animal models — positions it as a molecule of significant scientific interest for age-related cognitive decline research.

It must be emphasized that this is a preclinical study conducted in mice. Human pharmacokinetics, blood-brain barrier dynamics, immune responses, and baseline biology differ substantially from those of aged rodents. No claims about efficacy in humans can be made on the basis of this research alone. Controlled clinical trials are needed before any translational conclusions can be drawn.

Current Access and Compliance Context

GHK-Cu is currently available as a compounded peptide through licensed compounding pharmacies in the United States, typically prescribed by physicians practicing in the fields of anti-aging medicine, functional medicine, or integrative neurology. It is not approved by the U.S. Food and Drug Administration (FDA) as a drug for any specific indication, and it is not available over the counter as a therapeutic agent.

The regulatory landscape for compounded peptides continues to evolve. Patients and clinicians should be aware that access to specific peptides, including GHK-Cu, may vary by jurisdiction and is subject to ongoing regulatory review. Physicians who prescribe compounded peptides are expected to do so within the framework of an established patient-provider relationship, with documented clinical rationale.

For patients interested in GHK-Cu or other peptide therapies, working with a knowledgeable, licensed physician is essential to ensure appropriate screening, dosing decisions, and monitoring. The findings of studies like this one underscore that variables such as administration route and exposure duration are not trivial — they appear to meaningfully shape biological outcomes, and those decisions require clinical expertise.

What Patients Should Know

If you have encountered information about GHK-Cu and are curious about its potential role in healthy cognitive aging, here is what the current evidence supports — and where the gaps remain.

What the research suggests: This study found that GHK-Cu improved hippocampal-dependent learning in aged mice and produced measurable changes in inflammatory markers, synaptic proteins, and gene expression programs associated with aging biology. These findings are scientifically promising and warrant further investigation.

What remains unknown: Whether these findings translate to human cognitive aging is not yet established. The study was conducted in mice, and no human clinical trial data currently supports the use of GHK-Cu specifically for age-related cognitive decline. The optimal dose, route, duration, and patient population for any future human application remain areas of active research.

What you should do: If you are interested in peptide therapies as part of a personalized aging or brain health protocol, speak with a physician who is trained in peptide medicine and familiar with the current evidence base. Self-administration of compounded peptides without medical supervision is not recommended and may carry risks. A qualified provider can help you understand whether any emerging therapy is appropriate for your individual health profile.

Conclusion

The June 2026 preprint by Mazzola and colleagues represents a meaningful contribution to the science of peptide-based approaches to cognitive aging. By demonstrating that GHK-Cu can improve hippocampal-dependent learning in aged mice through biologically distinct mechanisms depending on how it is administered, the study opens important new questions about route optimization, sex-specific biology, and the molecular underpinnings of gerotherapeutic response. While human data remains essential before clinical recommendations can be made, this research adds to a growing foundation of evidence suggesting that endogenous peptides like GHK-Cu deserve rigorous scientific attention.

The Peptide Association is committed to helping patients and clinicians navigate this evolving field with access to evidence-based information and qualified medical professionals. To connect with a physician experienced in peptide medicine, visit peptideassociation.org/find-a-doctor.

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research discussed involves animal models, and findings may not be applicable to humans. Always consult a qualified, licensed healthcare provider before starting, stopping, or modifying any therapeutic regimen. The Peptide Association does not endorse any specific treatment protocol.

Citation (AMA Format):
Mazzola J, Rosenfeld M, Tucker M, et al. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Research Square. June 2026. doi:10.21203/rs.3.rs-9520102/v1. PMID: 42245779.